SCHEMBL5434348

SCHEMBL5434348

Cc1cc(Oc2ccc(S(C)(=O)=O)cc2)ccc1S(=O)(=O)N1CCc2ccccc2[C@H]1OC(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 2/20 0.39
TAS2R14 Q9NYV8 2/20 0.38
EPHX2 P34913 2/20 0.38
MMP1 P03956 2/20 0.38
AKR1C3 P42330 1/20 0.38
BCL2L1 Q07817 1/20 0.37
MCL1 Q07820 1/20 0.37
BAK1 Q16611 1/20 0.37
SLC9A3 P48764 2/20 0.36
FAAH O00519 1/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MMP2 P08253 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
MMP14 P50281 1/20 0.35
MMP15 P51511 1/20 0.35
MMP16 P51512 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165095 0.90 MMP12 (0.43) MMP12TAS2R14EPHX2MMP1AKR1C3
SCHEMBL5437354 0.89 MMP1 (0.46) TAS2R14MMP1AKR1C3SLC9A3ALDH1A1
SCHEMBL14427195 0.85 MMP12 (0.47) MMP12TAS2R14EPHX2MMP1AKR1C3
SCHEMBL14427192 0.83 MMP12 (0.58) MMP12EPHX2MMP1MMP2MMP7
SCHEMBL5435855 0.81 TAS2R14 (0.51) MMP12TAS2R14MMP1ALDH1A1LMNA
SCHEMBL5448028 0.80 MMP1 (0.44) MMP12TAS2R14MMP1AKR1C3ALDH1A1
SCHEMBL5430793 0.79 MMP8 (0.52) MMP12TAS2R14MMP1MEN1KMT2A
SCHEMBL5443161 0.79 THRB (0.49) TAS2R14MMP1MEN1KMT2AMMP2
SCHEMBL5439955 0.79 THRB (0.49) TAS2R14MMP1MEN1KMT2AMMP2
SCHEMBL5439640 0.79 MMP1 (0.50) TAS2R14MMP1ALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 US claimed
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS MMP9, MMP2, MMP3 MMP12 25/4885TAS2R14 3811/4885EPHX2 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.